Vontobel Holding
ITOS

Vontobel Holding’s iTeos Therapeutics ITOS Stock Holding History

Vontobel Holding’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-220,056
Closed -$2.41M – 1128
2023
Q4 		$2.41M Buy
220,056
+64,981
+42% +$644K 0.02% 405
2023
Q3 		$1.7M Buy
155,075
+8,499
+6% +$109K 0.02% 464
2023
Q2 		$1.94M Buy
146,576
+58,203
+66% +$830K 0.02% 447
2023
Q1 		$1.2M Buy
88,373
+30,611
+53% +$548K 0.01% 536
2022
Q4 		$1.13M Buy
+57,762
New +$1.13M 0.01% 544

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vontobel Holding's ITOS Position: Q1 2024 in Review

Vontobel Holding sold out of iTeos Therapeutics (ITOS) in Q1 2024, closing a stake of 220,056 shares — an estimated $2.41M sold.

Vontobel Holding first reported a position in ITOS in Q4 2022 and held it in 5 quarters. The position peaked at $2.41M in Q4 2023. 135 funds tracked by Wall St. Rank hold ITOS as of Q1 2024.

  • Vontobel Holding reported no remaining iTeos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Vontobel Holding sold 220,056 iTeos Therapeutics shares in Q1 2024, an estimated $2.41M.
  • Vontobel Holding first reported a position in iTeos Therapeutics in Q4 2022 and held it in 5 quarters.
  • Vontobel Holding's iTeos Therapeutics position peaked at $2.41M in Q4 2023.
  • 135 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2024.

Based on Vontobel Holding's 13F filing for Q1 2024, filed 10 May 2024.